BioLizard
PrivateLast Round
Grant
Jul 10, 2025
Total Funding Raised
$935,000
Company Overview
BioLizard operates in Healthcare & Life Sciences and is based in Belgium. Its latest recorded funding round was a Grant round in July 2025.
BioLizard is a bioinformatics and data engineering company that provides AI-driven solutions and services for the life sciences industry, enabling partners to transform complex biomedical data into actionable insights.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Healthcare Analytics, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Subscription SaaS, Government Contracts
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
BioLizard Comparables
Compare BioLizard with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| ClairLabs | 82% | |
| Genialis | 80% | |
| The Bioinformatics CRO | 79% |
For institutional investors. Book with your work email.
BioLizard Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jul 10, 2025 | ||||
| Grant | Mar 6, 2025 | ||||
| Seed | Sep 9, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
BioLizard Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Eurostars SME programme | Grant |
| Novalis Biotech | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Dec 9, 2025
Monthly visitors grew 102% MoM, reaching 8.5K.
- Nov 17, 2025
Dr. Alexander Scheer appointed as new CSO.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_awardOct 13, 2026
BioLizard Inc. receives the best poster award from the European Society for Spatial Biology for benchmarking cell segmentation methods for single-cell spatial transcriptomics.
- attends_eventOct 13, 2026
BioLizard Inc. receives the best poster award at the European Society for Spatial Biology (ESSB) conference for benchmarking cell segmentation methods for single-cell spatial transcriptomics.
For institutional investors. Book with your work email.
BioLizard Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about BioLizard's valuation, stock price, and market status.
Is BioLizard a public or private company?
BioLizard is a private company.
What is the current stock price of BioLizard?
BioLizard is a private company, so its shares have no public market price. Caplight tracks BioLizard's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is BioLizard worth (valuation)?
Valuation information for BioLizard is not publicly available.
Can I buy BioLizard stock?
BioLizard shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was BioLizard's last funding round?
BioLizard's most recent funding round was Grant on July 10, 2025.
Who are the main investors in BioLizard?
Key investors in BioLizard include Eurostars SME programme, Novalis Biotech.
Will BioLizard IPO soon?
No public IPO plans have been announced for BioLizard.
How can I track BioLizard secondary market activity?
Caplight tracks bids, offers, and trades in BioLizard's shares on secondary markets.